133 related articles for article (PubMed ID: 28747103)
21. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
Waldeck AR; Botteman MF; White RE; van Hout BA
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
[TBL] [Abstract][Full Text] [Related]
22. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
23. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
Schafer J; Galante D; Shafrin J
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
[TBL] [Abstract][Full Text] [Related]
24. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
[TBL] [Abstract][Full Text] [Related]
25. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
26. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
27. [Economic evaluation in oncology].
Schöffski O
Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
[TBL] [Abstract][Full Text] [Related]
28. The economic crisis and cancer chemotherapy: the role of the oncologist.
Rescigno P; Imbevaro S; Jirillo A
Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
[No Abstract] [Full Text] [Related]
29. Evidence, values, and funding decisions in Canadian cancer systems.
Peacock SJ; Regier DA; Raymakers AJN; Chan KKW
Healthc Manage Forum; 2019 Nov; 32(6):293-298. PubMed ID: 31645144
[TBL] [Abstract][Full Text] [Related]
30. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
31. Perspectives on Cost and Value in Cancer Care.
Saltz LB
JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
[No Abstract] [Full Text] [Related]
32. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
33. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
[TBL] [Abstract][Full Text] [Related]
34. Oncology phase II proof-of-concept studies with multiple targets: Randomized controlled trial or single arm?
Jemielita T; Tse A; Chen C
Pharm Stat; 2020 Mar; 19(2):117-125. PubMed ID: 31424631
[TBL] [Abstract][Full Text] [Related]
35. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
36. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
37. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S
Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898
[TBL] [Abstract][Full Text] [Related]
38. This is a call to oncologists for action.
Micó C; Berrocal A; Blasco A; Caballero C; Iranzo V; Lobo M; Camps C
Clin Transl Oncol; 2018 Dec; 20(12):1493-1501. PubMed ID: 29796999
[TBL] [Abstract][Full Text] [Related]
39. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.
Safonov A; Wang S; Gross CP; Agarwal D; Bianchini G; Pusztai L; Hatzis C
Breast Cancer Res Treat; 2016 Jan; 155(2):223-34. PubMed ID: 26749360
[TBL] [Abstract][Full Text] [Related]
40. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
